

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Shi Jian (石劍) (“**Dr. Shi**”) resigned as the employee representative supervisor of the Company with effect from May 15, 2026 due to personal career development reasons.

Dr. Shi has confirmed that he has no disagreement with the Board and the supervisory committee of the Company (the “**Supervisory Committee**”) and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited.

The Company would like to take this opportunity to express its sincere gratitude to Dr. Shi for his contribution to the Company during his tenure of service.

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is pleased to announce that Ms. Fang Lijuan (方麗娟) (“**Ms. Fang**”), the deputy director of the Antibody Platform Department of the Company, was democratically elected by the general meeting of employee representative as the employee representative supervisor of the second session of the Supervisory Committee on May 15, 2026. Pursuant to the articles of association of the Company, the election of employee representative supervisors are not subject to the approval of the Shareholders.

The term of office of Ms. Fang commenced on May 15, 2026 and will expire at the end of the second session of the Supervisory Committee. Ms. Fang will not receive any remuneration from the Company as the employee representative supervisor.

The biographical details of Ms. Fang are set out below:

Ms. Fang, aged 42, has 15 years of research experience in the research and development of therapeutic antibodies and fusion proteins in the biopharmaceutical industry. Ms. Fang worked at Guangzhou Hanfang Pharmaceutical Co., Ltd. (Guangzhou Hanfang) from 2006 to 2008, and joined the Company in 2011, successively serving as a scientist in the Antibody Engineering Technology Department and deputy director of the Antibody Platform Department.

Ms. Fang obtained her Bachelor's degree in Pharmaceutical Engineering from Wuhan University of Technology in 2006, and her Master's degree in Biology from Guangdong Pharmaceutical University in 2011.

Ms. Fang has confirmed that, save as disclosed above, as at the date of this announcement, she (i) did not hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) did not have other major appointments or professional qualifications; (iii) did not have any relationship with any director, supervisor, senior management, substantial shareholder or controlling shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; (iv) did not hold any other positions with the Company or other members of the Group; and (v) did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of other information in respect of Ms. Fang's appointment as the employee representative supervisor of the Company that is required to be disclosed pursuant to the requirements set out in Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the Shareholders.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, May 15, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.